StockData
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. (MAIA) stock

MAIANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$1.30+0.05 (+4.00%)

Close on Nov 18, 2026Market cap $79.07MP/E –Yield –

Earnings

MAIA Biotechnology's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue, Q3 FY2023
–
EPS, Q3 FY2023
-$0.36
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of MAIA Biotechnology's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2023ended Sep 30, 2023Nov 7, 2023before the open––-$0.36Release
Q2 FY2023ended Jun 30, 2023Aug 8, 2023before the open–––Release
Q1 FY2023ended Mar 31, 2023May 8, 2023before the open–––Release
Q4 FY2022ended Dec 31, 2022Mar 24, 2023after the close–––Release
Q3 FY2022ended Sep 30, 2022Nov 9, 2022after the close–––Release
Q2 FY2022ended Jun 30, 2022Aug 22, 2022before the open–––Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

MAIA Biotechnology has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When MAIA Biotechnology puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases MAIA Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K

  1. Update
  2. Update
  3. Update
  4. News
  5. News
  6. News
  7. Update
  8. News
  9. News
  10. News
  11. News
  12. News
  13. News
  14. Update
  15. News

See a number that looks wrong?